Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary & Life Sciences, Sir Graeme Davies Building, University of Glasgow, Glasgow, UK.
Curr Opin Rheumatol. 2014 Mar;26(2):197-203. doi: 10.1097/BOR.0000000000000037.
Autoimmune diseases such as rheumatoid arthritis (RA) pose an increasing, worldwide economic and health burden. Significantly, no cure exists for the majority of autoimmune diseases and consequently treatment is largely aimed at controlling disease symptoms. Therefore, there exists a critical need to develop new approaches that directly address the cause of disease, leading to disease remission and ultimately cure.
The organs, cells and molecules involved in the breach of self-tolerance have been partially defined in experimental models of autoimmunity. However, the broad applicability of this dogma in clinical disease is only partially understood. This gap between analyses of established disease and investigating early disease pathogenesis argues for the need for complementary studies in mice and humans.
Through a combination of clinical and experimental systems, novel autoantigens and neoepitopes involved in RA have been revealed. These have clear utility in predisease diagnosis and offer the possibility of antigen-specific immunotherapy. Ongoing experimental and clinical studies, for example using dendritic cell transfer, will facilitate a clearer understanding of the molecules, cells and organs that should be targeted to reinstate immunological tolerance. Antigen-specific immunotherapy therefore offers disease intervention without broad immunosuppression, and most importantly increases the likelihood of achieving true disease remission and cure.
类风湿关节炎(RA)等自身免疫性疾病在全球范围内造成的经济和健康负担日益加重。重要的是,大多数自身免疫性疾病尚无治愈方法,因此治疗主要集中在控制疾病症状上。因此,迫切需要开发新的方法,直接针对疾病的原因,从而实现疾病缓解,最终治愈。
在自身免疫性疾病的实验模型中,已部分定义了涉及自身耐受破坏的器官、细胞和分子。然而,这一教条在临床疾病中的广泛适用性仅部分得到理解。在对既定疾病的分析与对早期疾病发病机制的研究之间存在差距,这就需要在小鼠和人类中进行补充研究。
通过临床和实验系统的结合,已经揭示了与 RA 相关的新的自身抗原和新表位。这些在疾病前诊断中有明确的应用价值,并提供了抗原特异性免疫治疗的可能性。正在进行的实验和临床研究,例如使用树突状细胞转移,将有助于更清楚地了解应该靶向哪些分子、细胞和器官来恢复免疫耐受。因此,抗原特异性免疫治疗提供了疾病干预而不进行广泛的免疫抑制,最重要的是增加了实现真正疾病缓解和治愈的可能性。